desmethylsertraline desmethylsertraline desmethylsertraline (dms), also known as norsertraline, is an active metabolite of the antidepressant drug sertraline. like sertraline, desmethylsertraline acts as a monoamine reuptake inhibitor, and may be responsible for some of its parent's therapeutic benefits; however, the effects of dms's main activity of increasing serotonin levels via binding to the serotonin transporter appears to be negligible as in vivo testing showed no measurable change in brain activity despite a nearly 20-fold increase in dms blood levels compared to the ec50 (i.e. the amount required to achieve the desired effect in 50% of the population) of its parent drug sertraline. dms is significantly less potent relative to sertraline as a serotonin reuptake inhibitor (ki = 76 nm vs. 3 nm, respectively), but conversely, is more balanced as a monoamine reuptake inhibitor (5-ht (ki) = 76 nm; ne (ki) = 420 nm; da (ki) = 440 nm), which has the effective result of dms contrarily behaving as a serotonin-norepinephrine-dopamine reuptake inhibitor (sndri), with about 5.5-fold preference for inhibiting serotonin reuptake relative to catecholamine reuptake. desmethylsertralineclinical dataatc codenonelegal statuslegal status in general: uncontrolled pharmacokinetic dataelimination half-life66 hoursexcretionurineidentifiers iupac name (1s,4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine cas number87857-41-8pubchem cid114743chemspider102729uniicjj71o9be8chemblchembl40733comptox dashboard (epa)dtxsid60236666 chemical and physical dataformulac16h15cl2nmolar mass292.20 g·mol−13d model (jsmol)interactive image smiles clc1ccc(cc1cl)3c2c(cccc2)(n)cc3 dasotraline, a stereoisomer of dms, is also an sndri, and has been investigated for the potential clinical treatment of major depressive disorder, attention-deficit disorder, and eating disorders, but has not been approved or marketed for any indication.